Dexrazoxane

• Prevention of the cardiotoxicity of anthracyclines by reducing the iron-dependent free radical oxidative stress associated with anthracycline-induced cardiotoxicity through iron chelation.
• Antineoplastic effect by inhibition of topoisomerase II. Both mechanisms may contribute to the protective effect against tissue destruction after extravasation by anthracyclines.

• Cardioxane: Approved for the prophylaxis of chronic cumulative cardiotoxicity by use of doxorubicin or epirubicin in patients with advanced and/or metastatic cancer after prior anthracycline-containing treatment.
• Savene: treatment of extravasation by anthracyclines.

Notice! Regular monitoring of haematological parameters is urgently required.

• Cardioxane: 30 minutes before the anthracycline is administered as an i.v. infusion (15 minutes) in a dose corresponding to 20 times the doxorubicin equivalent dose or 10 times the epirubicin equivalent dose.
• Savene: Application is once daily i.v. for 3 consecutive days: 1000 mg/m2 KO on days 1 and 2 and 500 mg/m2 KO on day 3 The calculated dose must be administered over 1-2 hours as a slow intravenous infusion into a large vein of a limb/surface other than the limb/surface affected by lesions (extravasations).

  Remember! The first infusion should be given within the first 6 hours after a paravenous infusion.

Remember! Due to the cytotoxicity of Dexaroxan, sexually active men should practice effective contraception for at least 3 months after the end of treatment with Dexrazoxan.